Consistently, apparent side effects [29]. These findings show that AC1
microinjection into the ACC or systemic administration of could be a productive therapeutic target for neuropathic
GluN2B receptor selective antagonists inhibits behavioural pain and chronic inflammatory pain. Considering the fact
responses to peripheral inflammation. Recent studies in the that many signalling molecules that are important for ACC
insular cortex reveal that nerve injury also triggers the upregu- LTP overlap with those for hippocampal LTP, it is important
lation of NMDA GluN2B receptors [59]. Thus, the central to note that AC1 is unique in playing essential roles in differ-
NMDA GluN2B receptor is a potential drug target for control- ent forms of ACC LTP but not in hippocampal LTP.